Correction to “Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms”

Tao Yang, Mengshi Hu, Wenyan Qi, Zhuang Yang, Minghai Tang, Jun He, Yong Chen, Peng Bai, Xue Yuan, Chufeng Zhang, Kongjun Liu, Yulin Lu, Mingli Xiang, and Lijuan Chen*

J. Med. Chem. 2019, 62 (22), 10305–10320. DOI: 10.1021/acs.jmedchem.9b01348

In Figure 2A, the molecule structure in the cavity of the JAK2 protein was wrong. In Figure 6A, the last two pictures were the same. The correct figures are presented as follows.

Figure 2. (A) Docking result of the designed compound (molecule B) in the JAK2 protein (PDB code: 2XA4); (B) docking result of the designed compound (molecule B) in the FLT3 protein (PDB code: 4RT7).
Figure 6. (A) Cell cycle effects of 18e on MV4−11 cells. Cells were treated with increasing concentrations of 18e for 24 h, harvested, fixed, and stained with propidium iodide prior to flow cytometric analysis. (B) Effects of 18e on the induction of apoptosis.